Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776270 | 1.00 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL25210264 | 0.98 | L3MBTL1 (0.46) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL25226979 | 0.92 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL25204935 | 0.92 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL20176553 | 0.86 | L3MBTL1 (0.42) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL29776272 | 0.86 | L3MBTL1 (0.42) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL29776275 | 0.85 | CYP19A1 (0.47) | L3MBTL1MAPK1KDM4EMAPTTDP1 | |
| SCHEMBL20176547 | 0.85 | CYP19A1 (0.47) | L3MBTL1MAPK1KDM4EMAPTTDP1 | |
| SCHEMBL25228669 | 0.85 | PIK3CA (0.46) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL25204761 | 0.85 | PIK3CA (0.46) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2023-06-06 | — | — | US | disclosed |
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2023-06-06 | — | — | US | disclosed |
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2023-06-06 | — | — | US | disclosed |
| CN-110023305-B | Organic light-emitting compound and organic electroluminescent element using same | 索路思高新材料有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2018093231-A1 | ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING SAME | 주식회사 두산 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | OR10J3, ICMT, SLCO4C1 | NPC1 1168/4885RAB9A 3145/4885SMN1; SMN2 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.